Long-Term Outcomes of Increased Versus Conventional Adalimumab Dose Interval for Patients With Crohn's Disease in Stable Remission: 3-Year Follow-Up of the Randomized Controlled LADI Trial
Publication date
2026-02
Authors
van Lierop, Lisa M.A.
Devillers, Monique J.C.
van der Woude, C. Janneke
Hoentjen, Frank
de Vries, Annemarie C.
van Linschoten, Reinier C.A.
Jansen, Fenna M.
Broeder, Nathan den
de Jong, Dirk J.
Bodelier, Alexander
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by_nc_nd
Abstract
Keywords
Hepatology, Gastroenterology
Citation
van Lierop, L M A, Devillers, M J C, van der Woude, C J, Hoentjen, F, de Vries, A C, van Linschoten, R C A, Jansen, F M, Broeder, N D, de Jong, D J, Bodelier, A, West, R L, Gisbertz, I A M, Römkens, T E H, Boekema, P J, van Vroenhoven, H, Lutgens, M W M D, Bierens-Peters, D, Mujagic, Z, Wolfhagen, F H J, de Boer, N K, van Liere, E, Oldenburg, B, Naber, M R, van Bodegraven, A A, Mallant-Hent, R C, van der Meulen-de Jong, A E, ter Borg, P C J, Braat, H, Jansen, J M, Croix-Vingerling, R D L, Tan, A C I T L, Jansen, S V & van der Wiel, S 2026, 'Long-Term Outcomes of Increased Versus Conventional Adalimumab Dose Interval for Patients With Crohn's Disease in Stable Remission : 3-Year Follow-Up of the Randomized Controlled LADI Trial', Gastroenterology, vol. 170, no. 2, pp. 404-407. https://doi.org/10.1053/j.gastro.2025.09.023